Immunosuppressive management of Pediatric Kidney Transplant Recipients
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F20%3A10412724" target="_blank" >RIV/00216208:11130/20:10412724 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11140/20:10412724 RIV/00064203:_____/20:10412724
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=mZxrcHezpH" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=mZxrcHezpH</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2174/1381612826666200708133429" target="_blank" >10.2174/1381612826666200708133429</a>
Alternative languages
Result language
angličtina
Original language name
Immunosuppressive management of Pediatric Kidney Transplant Recipients
Original language description
Kidney transplantation is preferable treatment of children with end-stage kidney disease. All kidney transplant recipients including pediatric need immunosuppressive medications to prevent rejection episodes and graft loss. Induction therapy is used temporarily only immediately following transplantation while maintenance immunosuppressive drugs are started and given long-term. There is currently no consensus regarding the use of induction therapy in children, its use should be decided based on the immunological risk of the child. The recent progress shows that the recommended strategy is to use as maintenance immunosuppressive therapy a combination of a calcineurin inhibitor (preferably tacrolimus) with an antiproliferative drug (preferably mycophenolate mofetil) with steroids that can be withdrawn early or late in low-risk children. The mTOR-inhibitors (sirolimus, everolimus) are use rarely in pediatrics because of common side effects and no evidence of a benefit over calcineurin inhibitors. The use of calcineurin inhibitors, mycophenolate and mTOR-inhibitors should be followed by therapeutic drug monitoring. Immunosuppressive therapy of acute rejection consists of high-dose steroids and/or anti-lymphocyte antibodies (T-cell mediated rejection) or plasma exchange, intravenous immunoglobulines and/or rituximab (antibody mediated rejection). The future strategies for research are mainly precise characterisation of children needing induction therapy, more specific indications for mTOR-inhibitors and for the far future the possibility to reach the immuno tolerance.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30217 - Urology and nephrology
Result continuities
Project
<a href="/en/project/ED2.1.00%2F03.0076" target="_blank" >ED2.1.00/03.0076: Biomedical Centre of the Faculty of Medicine in Pilsen</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Current Pharmaceutical Design
ISSN
1381-6128
e-ISSN
—
Volume of the periodical
26
Issue of the periodical within the volume
28
Country of publishing house
NL - THE KINGDOM OF THE NETHERLANDS
Number of pages
9
Pages from-to
3451-3459
UT code for WoS article
000564275800010
EID of the result in the Scopus database
2-s2.0-85088168024